About Epizyme
Epizyme is a company based in Cambridge (United States) founded in 2007. Epizyme has raised $51.5 million across 6 funding rounds from investors including Kleiner Perkins, Royalty Pharma and Celgene. Epizyme operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Epizyme, Inc.
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$5.8 M (USD)10.32as on Mar 31, 2023
-
Net Profit
$661.79 K (USD)-5.82as on Mar 31, 2023
-
EBITDA
$5.02 M (USD)9.54as on Mar 31, 2023
-
Total Equity Funding
$51.5 M (USD)
in 6 rounds
-
Latest Funding Round
$270 M (USD), Post-IPO
Nov 05, 2019
-
Investors
Kleiner Perkins
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Epizyme
Unlock access to complete
Funding Insights of Epizyme
Epizyme has successfully raised a total of $51.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $270 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Epizyme
Epizyme has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Investment management services are provided to the life sciences industry.
|
Locked | Locked | Locked | |
|
Research and patient support for blood cancers are funded.
|
Locked | Locked | Locked |
Investor details for Epizyme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epizyme
Investment portfolio details for Epizyme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epizyme
Detailed financials for Epizyme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epizyme Comparisons
Peer comparison for Epizyme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epizyme
Epizyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Epizyme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epizyme
Complete news archive for Epizyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epizyme
Epizyme was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Epizyme is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Epizyme is a funded company, having raised a total of $51.5M across 6 funding rounds to date.
Annual revenue of Epizyme is $5.8M as on Mar 31, 2023.
Epizyme was founded in 2007 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where epigenetic therapies for cancer are developed. Lead candidates include TAZVERIK, approved for epithelioid sarcoma and follicular lymphoma, along with a protein arginine methyltransferase inhibitor targeted at solid tumors and blood cancers. Research and development efforts are centered on advancing these oncology solutions.
Epizyme's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Epizyme has 11 investors. Key investors include Kleiner Perkins, Royalty Pharma, Celgene, GSK, and Leukemia & Lymphoma Society.